Allakos Stock (NASDAQ: ALLK) stock price, news, charts, stock research, profile.
Open | $1.420 |
Close | - |
Volume / Avg. | 387.381K / 547.219K |
Day Range | 1.380 - 1.490 |
52 Wk Range | 0.980 - 5.640 |
Market Cap | $126.619M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 67 |
Short Interest | 8.99% |
Days to Cover | 15.37 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Allakos (NASDAQ: ALLK) through any online brokerage.
Other companies in Allakos’s space includes: Molecular Partners (NASDAQ:MOLN), Cellectar Biosciences (NASDAQ:CLRB), FibroGen (NASDAQ:FGEN), Vistagen Therapeutics (NASDAQ:VTGN) and Tevogen Bio Holdings (NASDAQ:TVGN).
The latest price target for Allakos (NASDAQ: ALLK) was reported by JMP Securities on Wednesday, January 17, 2024. The analyst firm set a price target for 3.00 expecting ALLK to rise to within 12 months (a possible 109.79% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Allakos (NASDAQ: ALLK) is $1.43 last updated May 20, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Allakos.
Allakos’s Q2 earnings are confirmed for Wednesday, August 7, 2024.
There is no upcoming split for Allakos.
Allakos is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.